Novartis Pharmaceutical Corp. of East Hanover today announced that new data from a large, international clinical trial found promising results with certain leukemia patients.Novartis Pharmaceutical ...

In 2001, a Time Magazine cover story touted Novartis’ targeted leukemia treatment Gleevec (imatinib) as a new kind of “ammunition in the war against cancer.” Along with a picture of the Gleevec pills, ...

Imatinib is an oral targeted therapy used for several cancers and other conditions caused by specific genetic mutations. The medication is approved for: Philadelphia chromosome positive chronic ...

Continuous Gleevec treatment in GIST patients significantly prolongs progression-free survival and delays resistance compared to treatment interruption. Median progression-free survival was 6.1 months ...

Ziftomenib plus Gleevec is being tested in a phase 1 trial for advanced GIST after Gleevec progression, showing promise in preclinical models. The combination targets GIST tumor weaknesses via a ...